NICE has developed a medtech innovation briefing (MIB) on the AliveCor Heart Monitor and AliveECG app for detecting atrial fibrillation.

In October 2016 we updated this advice to reflect a change in the name of the technology, from AliveCor Heart Monitor to Kardia Mobile. AliveCor Heart Monitor and Kardia Mobile are functionally identical.

NICE has also produced related diagnostics guidance on lead-I ECG devices for detecting symptomatic atrial fibrillation using single time point testing in primary care.

Medtech innovation briefings provide a description of the medical technology, including its likely place in therapy, the costs of using the technology and a critical review of the strengths and weaknesses of the relevant published evidence. Their purpose is to provide objective information on device and diagnostic technologies to aid local decision-making by clinicians, managers and procurement professionals. By making this information available, NICE helps to avoid the need for NHS organisations to produce similar information for local use.

Medtech innovation briefings are not NICE guidance. They differ in format, contain no judgement on the value of the technology and do not constitute a guidance recommendation.

MIBs are commissioned by NHS England and produced in support of the NHS 5 Year Forward View, specifically as one of a number of steps which will accelerate innovation in new treatments and diagnostics.